8-K: Summit Therapeutics Partner Akeso Announces Positive Phase III Trial Results for Ivonescimab in Lung Cancer

Akeso, partner of Summit Therapeutics, reports that ivonescimab in combination with chemotherapy demonstrated statistically significant superiority in progression-free survival compared to tislelizumab in treating squamous NSCLC in the HARMONi-6 Phase III trial.

Summary

• Summit Therapeutics' partner, Akeso, announced positive results from the HARMONi-6 Phase III clinical trial.
• The trial evaluated ivonescimab in combination with platinum-based chemotherapy versus tislelizumab (a PD-1 inhibitor) plus chemotherapy for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
• Ivonescimab plus chemotherapy showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to tislelizumab plus chemotherapy.
• The PFS benefit was observed in patients with both PD-L1-positive and PD-L1-negative tumors.
• No new safety signals were identified in the study.
• The full data set will be presented at an upcoming major medical conference later this year.
• Summit Therapeutics is currently enrolling patients in the HARMONi-3 study, a multiregional Phase III trial evaluating ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy in first-line metastatic NSCLC.
• Summit has also begun to activate clinical trial sites in the United States for HARMONi-7.
• Over 2,300 patients have been treated with ivonescimab in clinical studies globally.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, suggesting a promising future for ivonescimab. The sentiment is optimistic due to the potential for improved treatment outcomes in NSCLC.

Positives

• Ivonescimab demonstrated a statistically significant and clinically meaningful improvement in PFS compared to tislelizumab in the HARMONi-6 trial.
• The PFS benefit was observed regardless of PD-L1 expression.
• No new safety signals were identified.
• Ivonescimab has the potential to become a next-generation treatment option for solid tumors, starting with NSCLC.
• Ivonescimab was approved for marketing authorization in China in May 2024.
• Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

Risks

• The HARMONi-6 trial was conducted in China, and the results may not be directly applicable to other regions.
• Ivonescimab is still an investigational therapy and is not approved by regulatory authorities in Summit's license territories, including the United States and Europe.
• The success of the HARMONi-3 and HARMONi-7 trials is not guaranteed.
• Clinical trials are subject to delays, regulatory hurdles, and other unforeseen challenges.

Future Outlook

Summit Therapeutics is focused on the clinical development of ivonescimab in NSCLC, with ongoing Phase III trials (HARMONi-3 and HARMONi-7) and plans to present the full data set from the HARMONi-6 trial at an upcoming medical conference. Top-line results from HARMONi are expected in the middle of this year.

Management Comments

• Ivonescimab has the opportunity to make a significant, positive difference, potentially providing patients with the next generation of treatment options against insidious solid tumors beginning with non-small cell lung cancer, stated Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit.
• Our aligned mission with Akeso seeks to bring ivonescimab to as many patients around the world who can potentially benefit as quickly as possible, added Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit.
• We are incredibly proud of Akeso's accomplishment with the HARMONi-6 trial, added Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit.

Industry Context

The announcement highlights the competitive landscape in NSCLC treatment, where companies are striving to improve upon existing PD-(L)1 inhibitor therapies. Ivonescimab's potential to demonstrate superior efficacy compared to PD-1 inhibitors in combination with chemotherapy could position it as a significant player in the NSCLC market.

Comparison to Industry Standards

• The press release states that prior to HARMONi-6, there were no known Phase III clinical trials in NSCLC which have shown a statistically significant improvement compared to PD-(L)1 inhibitor therapy in combination with chemotherapy in a head-to-head setting.
• This suggests that ivonescimab's performance in HARMONi-6 is a notable achievement compared to existing treatment options like pembrolizumab (Keytruda) and nivolumab (Opdivo) when combined with chemotherapy.
• The success of Akeso's HARMONi-2 study in China, where a PFS benefit was observed in a monotherapy setting for patients whose squamous or non-squamous tumors were positive for PD-L1 expression, further supports the potential of ivonescimab-based regimens.

Stakeholder Impact

• Positive results could lead to improved treatment options and outcomes for NSCLC patients.
• Successful development and commercialization of ivonescimab could benefit Summit Therapeutics' shareholders.
• The partnership between Summit Therapeutics and Akeso is strengthened by the positive trial results.

Next Steps

• Presentation of the full data set from the HARMONi-6 trial at an upcoming major medical conference.
• Continued enrollment in the HARMONi-3 trial.
• Activation of clinical trial sites in the United States for HARMONi-7.
• Anticipated top-line results from HARMONi in the middle of this year.

Key Dates

Keywords

ivonescimab, Summit Therapeutics, Akeso, NSCLC, lung cancer, clinical trial, HARMONi-6, PFS, tislelizumab, chemotherapy, oncology, SMT112, AK112